Published on Friday, May 25, 2018 by Dilip Davda
ZIM Laboratories Ltd. (ZLL) is a pioneer in drug delivery solutions, targeting patient convenience and adherence. ZIM stands for Zeal for Innovative Medicines solutions. It uses proprietary technologies to manufacture differentiated products making the benefits available to customers as affordable solutions.
From Nagpur, Central India, ZLL is EU-GMP, WHO-GMP certified and ISO 9001:2008 accredited. It is engaged in the activities of R and D, manufacturing, distribution, marketing of oral solid dosage, pre-formulations and orally disintegrating strips. As on 30.11.17 it has a basket of 31 products under orally disintegrating strips.
ZLL came with its maiden IPO at par in 1994 and was listed on OTCEI. As this exchange closed functioning since 1997, ZIM was trying for delist and buyback offer. However, as it also got some PE funds investment and they needed exit route, ZIM has finally decided to get it listed on BSE Main Board.
It is likely to be listed by first fortnight of June 2018. According to market sources, there were buying offer flooded in the markets few months back from some informed investors who were ready to offer Rs. 120 per share.
On performance front, for nine months ended on 31.12.17, it has earned net profit of Rs. 11.34 crore on a turnover of Rs. 204.58 crore.
As on 31.03.18, there were 4319 shareholders in paid up equity capital of Rs. 8.06 crore. ZLL’s reserve and surplus stood at Rs. 120 crore plus as on 31.12.17. Its products are well accepted globally. Its client list includes Cipla, Zydus, Alkem, Abbott, Emcure, USV, Dr. Reddy’s etc.
No record Found